image
Healthcare - Biotechnology - NASDAQ - US
$ 2.2109
-5.7 %
$ 90.3 M
Market Cap
-3.03
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ORMP stock under the worst case scenario is HIDDEN Compared to the current market price of 2.21 USD, Oramed Pharmaceuticals Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ORMP stock under the base case scenario is HIDDEN Compared to the current market price of 2.21 USD, Oramed Pharmaceuticals Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ORMP stock under the best case scenario is HIDDEN Compared to the current market price of 2.21 USD, Oramed Pharmaceuticals Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ORMP

image
$2.7$2.7$2.6$2.6$2.5$2.5$2.4$2.4$2.3$2.3$2.2$2.2$2.1$2.1$2.0$2.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
1.34 M REVENUE
-50.43%
-15.8 M OPERATING INCOME
61.16%
5.09 M NET INCOME
113.47%
-10.3 M OPERATING CASH FLOW
63.12%
-73 M INVESTING CASH FLOW
-241.76%
52 M FINANCING CASH FLOW
382.22%
0 REVENUE
0.00%
-3.09 M OPERATING INCOME
1.47%
-19.6 M NET INCOME
-213.41%
-7.1 M OPERATING CASH FLOW
-342.05%
-34.3 M INVESTING CASH FLOW
-36.19%
-1.29 M FINANCING CASH FLOW
95.77%
Balance Sheet Oramed Pharmaceuticals Inc.
image
Current Assets 163 M
Cash & Short-Term Investments 162 M
Receivables 0
Other Current Assets 537 K
Non-Current Assets 58 M
Long-Term Investments 56.4 M
PP&E 1.57 M
Other Non-Current Assets 34 K
73.47 %25.56 %Total Assets$220.6m
Current Liabilities 53.2 M
Accounts Payable 551 K
Short-Term Debt 51.3 M
Other Current Liabilities 1.38 M
Non-Current Liabilities 4.44 M
Long-Term Debt 342 K
Other Non-Current Liabilities 4.1 M
88.94 %7.11 %Total Liabilities$57.7m
EFFICIENCY
Earnings Waterfall Oramed Pharmaceuticals Inc.
image
Revenue 1.34 M
Cost Of Revenue 0
Gross Profit 1.34 M
Operating Expenses 17.1 M
Operating Income -15.8 M
Other Expenses -20.9 M
Net Income 5.09 M
10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)1m01m(17m)(16m)21m5mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-1176.79% OPERATING MARGIN
-1176.79%
412.31% NET MARGIN
412.31%
3.37% ROE
3.37%
2.51% ROA
2.51%
-7.21% ROIC
-7.21%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Oramed Pharmaceuticals Inc.
image
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)20152015201620162017201720182018201920192020202020212021202220222023202320242024
Net Income 5.09 M
Depreciation & Amortization 196 K
Capital Expenditures -254 K
Stock-Based Compensation 4.21 M
Change in Working Capital -2.7 M
Others -17.6 M
Free Cash Flow -10.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Oramed Pharmaceuticals Inc.
image
ORMP has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 20
6. Ownership
Insider Ownership Oramed Pharmaceuticals Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the “offering”) whereby an affiliate of Oramed Pharmaceuticals Inc. (“Oramed”) (Nasdaq: ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share. globenewswire.com - 1 month ago
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology NEW YORK , April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that it has successfully closed a strategic investment in Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®. prnewswire.com - 1 month ago
Oramed Pharmaceuticals Issues Letter to Shareholders Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials. Distribution of majority of Oramed's holding in OraTech to Oramed shareholders via dividend planned to coincide with OraTech's public listing. prnewswire.com - 3 months ago
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed shareholders to receive the right to a direct stake in OraTech, expected to go public on Nasdaq. OraTech will have global marketing rights to Oramed's POD™ oral protein delivery technology. prnewswire.com - 4 months ago
3 Micro-Cap Moonshots for Fearless Investors When discussing micro-cap stocks, it's important to recognize their general overlap with the world of penny stocks. These stocks trade as shares of companies with market capitalizations between $50 million and $300 million. investorplace.com - 11 months ago
Oramed Letter to Shareholders Initiating Phase 3 oral insulin trial in the United States under a new protocol  JV with Chinese Partner, HTIT Scilex Senior Secured Note PeriTech Asset Purchase & Strategic Out-licensing  NEW YORK , Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron. Dear Shareholders, I am pleased to share with you an update regarding Oramed. prnewswire.com - 1 year ago
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company 18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note with Scilex replaces Oramed's previously announced Stock Purchase Agreement and DIP Term Loan with Sorrento Therapeutics NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE:ORMP) today announced that on September 21, 2023, Oramed and Scilex Holding Company ("Scilex") entered into a Securities Purchase Agreement pursuant to which Scilex issued a Senior Secured Promissory Note (the "Note") to Oramed. prnewswire.com - 1 year ago
Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally JV will have global marketing rights to oral drug delivery technology HTIT to invest $60 million, Oramed to invest $10 million into JV HTIT to provide a supply agreement for oral insulin capsule JV to advance registration of oral insulin in the United States and other countries NEW YORK , Aug. 2, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com) announced today that it has signed a non-binding term sheet with Hefei Tianhui Biotech Co., Ltd. ("HTIT") to establish a joint venture ("JV") based on Oramed's oral drug delivery technology. prnewswire.com - 1 year ago
Best Penny Stocks To Buy Today? 4 To Watch Under $5 Penny stocks under $5 to watch this week. The post Best Penny Stocks To Buy Today? pennystocks.com - 2 years ago
Why Oramed Pharmaceuticals Stock Is Crashing Today The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes. fool.com - 2 years ago
Why Is Oramed (ORMP) Stock Down 75% Today? Oramed (NASDAQ: ORMP ) stock is falling hard on Thursday after releasing data from a Phase 3 clinical trial. This clinical trial saw Oramed testing the efficiency of ORMD-0801 in patients with Type 2 Diabetes at 26 weeks against those taking a placebo. investorplace.com - 2 years ago
Oramed's oral insulin pill fails; stock is down 72% Shares of Oramed Pharmaceuticals Inc. ORMP, +5.78% plunged 72% in premarket trading on Thursday, the day after the company told investors its oral insulin medication did not meet the primary or secondary endpoints in a Phase 3 clinical trial. The randomized, double-blind, placebo-controlled trial compared Oramed's treatment to placebo to see if it improved glycemic control in patients with type 2 diabetes. marketwatch.com - 2 years ago
8. Profile Summary

Oramed Pharmaceuticals Inc. ORMP

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 90.3 M
Dividend Yield 0.00%
Description Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Contact 1185 Avenue of the Americas, New York City, NY, 10036 https://www.oramed.com
IPO Date May 1, 2007
Employees 13
Officers Dr. Miriam Kidron Ph.D. Chief Scientific Officer & Director Mr. Joshua Hexter Chief Operating & Business Officer Mr. Nadav Kidron Esq. President, Chief Executive Officer & Executive Chairman Mr. Avraham Gabay Chief Financial Officer, Treasurer & Secretary